Literature DB >> 10722443

Prospects for control of herpes simplex virus disease through immunization.

L R Stanberry1, A L Cunningham, A Mindel, L L Scott, S L Spruance, F Y Aoki, C J Lacey.   

Abstract

Herpes simplex viruses (HSVs) can cause a variety of infections, including genital herpes. Despite effective antiviral therapy, HSV infections remain a significant worldwide public health problem. Vaccines offer the best hope for controlling spread and limiting HSV disease. This article discusses the pathogenesis and immunobiology of mucocutaneous HSV infections, summarizes the spectrum of diseases caused by HSV, and provides a review of the field of HSV vaccine research. This article also discusses what might be realistically expected of a vaccine intended for control of genital herpes and explores the question of whether a vaccine that is effective in controlling genital HSV disease might also be effective in controlling nongenital HSV disease. The efficacy of such vaccines for the full spectrum of HSV disease will eventually determine the timing and targeting of immunization, ranging from selective immunization in preadolescence to universal childhood immunization as part of the routine childhood regimen.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10722443     DOI: 10.1086/313687

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  47 in total

1.  Construction, phenotypic analysis, and immunogenicity of a UL5/UL29 double deletion mutant of herpes simplex virus 2.

Authors:  X Da Costa; M F Kramer; J Zhu; M A Brockman; D M Knipe
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Therapeutic Options for Herpes Simplex Infections.

Authors:  Eugene Au; Stephen L. Sacks
Journal:  Curr Infect Dis Rep       Date:  2003-02       Impact factor: 3.725

3.  Towards an effective genital herpes vaccine: past lessons and future prospects.

Authors:  William P Halford
Journal:  Future Virol       Date:  2007-01-01       Impact factor: 1.831

4.  Therapeutic immunization with a virion host shutoff-defective, replication-incompetent herpes simplex virus type 1 strain limits recurrent herpetic ocular infection.

Authors:  Tammie L Keadle; Lynda A Morrison; Jessica L Morris; Jay S Pepose; Patrick M Stuart
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

5.  Increase in rates of herpes simplex virus type 1 as a cause of anogenital herpes in western Sydney, Australia, between 1979 and 2003.

Authors:  L J Haddow; B Dave; A Mindel; K A McPhie; C Chung; C Marks; D E Dwyer
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

6.  Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: a phase II, randomized, double-blind, placebo-controlled study.

Authors:  Timothy W Schacker; Marcus Conant; Christopher Thoming; Tamara Stanczak; Zengri Wang; Michael Smith
Journal:  Antimicrob Agents Chemother       Date:  2002-10       Impact factor: 5.191

7.  A replication-competent, neuronal spread-defective, live attenuated herpes simplex virus type 1 vaccine.

Authors:  Elizabeth E Brittle; Fushan Wang; John M Lubinski; Ralph M Bunte; Harvey M Friedman
Journal:  J Virol       Date:  2008-06-18       Impact factor: 5.103

8.  Predominance of herpes simplex virus type 1 from patients with genital herpes in Nova Scotia.

Authors:  Kevin R Forward; Spencer Hs Lee
Journal:  Can J Infect Dis       Date:  2003-03

9.  Immunization with a dominant-negative recombinant Herpes Simplex Virus (HSV) type 1 protects against HSV-2 genital disease in guinea pigs.

Authors:  Richard Brans; Feng Yao
Journal:  BMC Microbiol       Date:  2010-06-03       Impact factor: 3.605

10.  Herpes simplex virus 2 ICP0 mutant viruses are avirulent and immunogenic: implications for a genital herpes vaccine.

Authors:  William P Halford; Ringo Püschel; Brandon Rakowski
Journal:  PLoS One       Date:  2010-08-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.